A practical, budget-conscious walkthrough of WIPO ST.26 requirements, from first provisional to PCT and national filings
1. Why Sequence Listings Matter to Early-Stage Ventures
For a biotech venture, the patent portfolio is often the main asset on the balance sheet. Investors, licensing partners and acquirers will review it closely. A sequence listing that is missing, malformed, or inconsistent with the specification can result in an incomplete application, requests for correction and doubts about the quality of the filing.
Pre-revenue and crowdfunded companies face particular constraints. Budgets are limited, the team may be small and scientific rather than legal and the company may be communicating publicly about its technology to attract backers. This guide explains what the sequence listing requirement is, how to prepare one at low cost and how to avoid the mistakes most common in early filings.
| Scope note. This guide focuses on U.S. practice and the international standard used by the PCT and many national offices. Requirements differ in detail by jurisdiction, so confirm with your patent attorney and the current rules of each office before filing. |
2. The Legal and Technical Framework
- WIPO Standard ST.26. Since July 1, 2022, the USPTO and other offices, including for international PCT applications, require sequence listings in the XML-based ST.26 format. The earlier ST.25 text format is no longer accepted for new applications filed on or after that date.
- U.S. rules. The USPTO’s sequence listing rules appear in 37 C.F.R. §§ 1.831 to 1.835, which replaced the earlier rules in §§ 1.821 to 1.825 for applications covered by ST.26.
- Separate file, not counted in page fees. The sequence listing is submitted as an XML file and, in the U.S., it does not count toward specification page count for fee purposes.
- Part of the disclosure. The sequence listing forms part of the application as filed. It cannot be used to add subject matter that is not already disclosed in the application and a later-filed corrected listing must not introduce new matter.
What triggers the requirement
The standard requires listing sequences that are “disclosed” in the application, meaning described in the specification, claims, drawings, or elsewhere, if they meet defined thresholds:
| Sequence type | Threshold (summary) | Notes |
| Nucleotide sequences | 10 or more specifically defined nucleotides | DNA and RNA, including modified bases that are annotated according to the standard |
| Amino acid sequences | 4 or more specifically defined amino acids | Includes D-amino acids and modified residues with annotation and peptides with some non-natural elements |
| Branched or looped sequences | Generally outside the scope, or handled with special rules | Check the standard’s treatment of the specific structure |
| Sequences in figures and tables | Included if they meet the thresholds | A sequence shown only as an image still counts as disclosed |
These thresholds are summarised and the full definitions of “specifically defined” nucleotides and amino acids and of sequences that are excluded, are in the standard and the USPTO’s guidance. When in doubt, include the sequence.
Provisional applications
A provisional application is not examined and usually does not require a compliant sequence listing at filing, although practice should be confirmed with the current USPTO rules. Even so, including the sequences clearly in the text and preferably in a draft ST.26 file, is useful: it ensures that the written description supports later claims and it lets you build the non-provisional listing from a clean starting point. Remember that only what is disclosed in the provisional can support the priority claim.
3. Public Disclosure Risk for Crowdfunded Ventures
A crowdfunding campaign, investor deck, preprint, conference poster, or social-media post that discloses a sequence can be a public disclosure that affects patentability.
- U.S. grace period. In the United States, an inventor’s own disclosure made within one year before the effective filing date is generally excepted from prior art under 35 U.S.C. § 102(b)(1), although the exception has conditions and should not be relied on casually.
- Absolute novelty elsewhere. Many jurisdictions, including the European Patent Convention states and China, have no general grace period or only narrow ones. A public disclosure before filing can destroy novelty abroad.
- Third-party reposting. Backers, journalists and platform operators can republish campaign materials and the date of first public accessibility can be difficult to control.
- Securities and consumer-protection obligations. Crowdfunding rules require accurate descriptions of the business. Counsel should balance the need for investor disclosure with the need to keep technical details confidential until patent filings are made.
| Recommended sequence of events: (1) file at least a well-supported provisional application that includes all key sequences; (2) then publish campaign materials; (3) use general descriptions of the technology without sequences or critical details; (4) put detailed data in a confidential data room under non-disclosure agreements. |
4. Preparing a Sequence Listing, Step by Step
4.1 Identify every sequence
- Search the specification, claims, drawings, tables, examples and any sequence data appendices for sequences that meet the thresholds.
- Assign a stable internal ID to each, then map it to its future SEQ ID NO.
- Check that the same sequence is not listed twice under different names and that sequences in figures match those in the text.
- Decide on the order of the SEQ ID NOs. Many drafters follow the order of first appearance in the specification, which makes cross-checking easier.
4.2 Create the XML file with the WIPO Sequence tool
WIPO offers a free desktop application, WIPO Sequence, for creating and validating ST.26 listings. It lets users enter or import sequences, add feature annotations and run the same validation checks that offices use. Commercial software and patent-attorney services also exist and may be useful when the portfolio is large or the sequences include many modifications. A typical workflow is:
- Start a new sequence listing project and enter the general information: applicant name, invention title, the applicant’s file reference and earliest priority information where applicable.
- Add each sequence. For nucleotide sequences, indicate whether DNA or RNA and for amino acid sequences, enter using the standard one-letter or three-letter codes allowed by the tool.
- Mark organism information and annotate features, including modified residues, variants and artificial sequences, as required by the standard.
- Assign each sequence its SEQ ID NO and keep these consistent with the specification and claims.
- Run the validator and fix every error and warning. Warnings may not prevent filing, but should be understood.
- Generate the XML file and keep a copy of the project file for future edits.
4.3 Annotate carefully
Annotation is where most mistakes happen. Features such as modified bases, non-standard amino acids, signal peptides, binding sites, or variants must be described with the controlled terms (feature keys and qualifiers) the standard specifies. Key points:
- Unknown or variable positions. Use the permitted ambiguity symbols, such as “n” for any nucleotide and “X” for any amino acid and add the necessary annotations when a position has a defined set of alternatives.
- Artificial and engineered sequences. The organism field should reflect that the sequence is artificial where appropriate, with a note on the source.
- Modified residues. Use the standard’s controlled vocabulary for each modification and indicate the position.
- Multi-chain or fusion constructs. List each chain as its own sequence when it meets the thresholds and describe relationships in the text.
4.4 Align the text, claims and listing
- Refer to each sequence in the description and claims by its SEQ ID NO.
- Check that sequences recited in claims by identity or by mutation positions correspond to the SEQ ID NO in the listing and that numbering conventions are stated.
- Make sure that all sequences in the listing appear in the text, or are expressly incorporated by the text. Do not insert sequences that were not otherwise disclosed in the application as filed.
- Include the sequence listing information in the application data transmittal as the Office requires.
4.5 File correctly
- Submit the XML file through the USPTO’s Patent Center, choosing the correct document description for the sequence listing and confirm that the system validates it.
- For PCT applications, follow the receiving office’s procedure. The sequence listing is part of the description and is handled separately for filing and for search purposes.
- Keep a record of the file name, checksum and date of filing, together with the draft versions.
5. Budget-Conscious Tips
| Cost area | Low-cost approach | Watch out for |
| Drafting and annotation | Use the free WIPO Sequence tool and assign one team member to learn it well | Time spent by scientists on annotation rules; do not skip the validator |
| Attorney review | Prepare a clean spreadsheet of sequences, names, sources and modifications before engaging counsel | Disorganised inputs raise billable time and the risk of mistakes |
| Conversion from older formats | Use the conversion features in the tool, then review manually | Automatic conversion may mis-handle modified residues and ambiguous positions |
| Corrections after filing | Validate before filing and cross-check against the text twice | Notices to comply may bring deadlines, fees and extra attorney time |
| Foreign filings | Use one ST.26 file for PCT and national phases where accepted | Local formal requirements and translation of descriptive text |
| Provisional stage | Include all sequences in the text and keep a draft listing | Do not defer sequence data to later, since provisional support is limited to what is disclosed |
- Maintain a single source of truth. Store sequences in one controlled spreadsheet or database with version history, rather than scattered across lab notebooks and slides.
- Reuse the work. A well-built listing for the provisional can be updated for the non-provisional and the PCT filing, saving time and reducing inconsistency.
- Know when to pay for help. A bioinformatics-literate patent professional can save money on complex listings with many annotations, variants, or modified residues.
6. Common Errors and How to Avoid Them
| Error | Consequence | Prevention |
| Sequence disclosed in text or figure but omitted from the listing | Notice requiring a corrected listing; risk of questions about completeness | Search the whole application for sequences before finalising |
| SEQ ID NO. mismatch between the listing, description and claims | Confusion in examination; possible indefiniteness | Build a cross-reference table and verify it |
| Using an outdated ST.25 file | Rejection of the file by the Office’s system | Create all new listings in ST.26 from the start |
| Incorrect annotation of modified residues | Validation errors, or a listing that does not accurately describe the molecule | Learn the controlled vocabulary; review with a bioinformatics specialist |
| Adding sequences not in the original application | New-matter issues; a listing cannot cure a lack of disclosure | Compare the final listing against the application as filed |
| Sequences too short or not “specifically defined” included or excluded in error | Unnecessary entries or omissions | Apply the thresholds carefully and consult the standard |
| Inconsistent organism or origin descriptions | Confusing records for examiners and later due diligence | Standardise how the source and artificial origin are described |
| No archived project file | Heavy rework for later filings | Archive the project file with each filing |
7. Beyond Filing: Using Sequences Strategically
- Prior-art searching. Run sequence searches in public databases and patent sequence repositories before drafting claims, to understand how much room there is.
- Claim strategy. The listing supports claims that recite specific sequences and the specification must also support any broader sequence-identity or functional claims. Early-stage data should be used to justify claim breadth, as described in modern enablement and written-description case law.
- Due diligence readiness. Maintain a data-room folder with the latest listing, the validator output, the filing receipts and a table linking each sequence to claims, experiments and any deposits.
- Updates for new variants. New sequences discovered after filing generally need new applications, because they cannot be added to existing ones. Plan continuation or new-filing schedules accordingly.
- Freedom to operate. Search for third-party patents that disclose or claim similar sequences and keep records.
8. Pre-Filing Checklist
| Item | |
| ☐ | A provisional application including all key sequences is filed before any public disclosure. |
| ☐ | Every sequence meeting the thresholds is identified from the specification, claims, drawings and tables. |
| ☐ | The listing is built as an ST.26 XML file, using the WIPO Sequence tool or equivalent. |
| ☐ | Validator run with all errors resolved and warnings reviewed. |
| ☐ | Annotations for modified residues, variants and artificial sequences are checked. |
| ☐ | SEQ ID NOs are used consistently in the text, claims and listing. |
| ☐ | No sequence is in the listing that is not disclosed in the application. |
| ☐ | The file is submitted in the correct document category through Patent Center, or through the PCT receiving office. |
| ☐ | Project file, spreadsheet and filing evidence are archived. |
| ☐ | Crowdfunding and investor materials reviewed to avoid premature disclosure of sequences. |
9. Conclusion
The sequence listing is a small part of a biotech patent application, but it is a technical requirement that can cause outsized trouble if handled late or carelessly. For pre-revenue and crowdfunded ventures, the winning approach is straightforward: file early, keep sequence data organised, use the free ST.26 tools, validate before filing and manage public disclosures with care. Doing so protects the company’s most important intangible assets, avoids avoidable costs and presents a clean record to the investors and partners who will inspect it.
This article is provided for general informational purposes and is not legal advice. Statutes, rules, fee schedules and USPTO practice change; confirm current requirements and consult a registered patent practitioner or trademark attorney before relying on any point here.
